Add to ORKGInitial severity of the patient before clinical trial is considered as the main predictor of therapy success in alcoholism. This result was found from a Meta-analysis with 4457 patients
Objectives: To determine the effectiveness and tolerability of acamprosate in comparison to placebo...
A population of 127 alcoholics of both sexes, hospitalized and weaned (DSM III diagnose: Alcohol Abu...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
Initial severity of the patient before clinical trial is considered as the main predictor of therapy...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
This secondary analysis of the first U.S. acamprosate trial (N = 601) for alcohol dependence examine...
Meta-analysis based on an international open label prospective study has shown that abstinence durin...
Acamprosate was shown to help to maintain abstinence on alcoholic patients. In this paper, we show t...
Abstract — Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal ...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
general study on compliance conditions throughout a meta-analysis of 4354 patients treated with acam...
Naturalistic randomised study controlled against any other treatment to assess the effect of acampro...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Objective. To examine whether the addition of acamprosate to Cognitive Behavioural Therapy (CBT) out...
Objectives: To determine the effectiveness and tolerability of acamprosate in comparison to placebo...
A population of 127 alcoholics of both sexes, hospitalized and weaned (DSM III diagnose: Alcohol Abu...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
Initial severity of the patient before clinical trial is considered as the main predictor of therapy...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
This secondary analysis of the first U.S. acamprosate trial (N = 601) for alcohol dependence examine...
Meta-analysis based on an international open label prospective study has shown that abstinence durin...
Acamprosate was shown to help to maintain abstinence on alcoholic patients. In this paper, we show t...
Abstract — Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal ...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
general study on compliance conditions throughout a meta-analysis of 4354 patients treated with acam...
Naturalistic randomised study controlled against any other treatment to assess the effect of acampro...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Objective. To examine whether the addition of acamprosate to Cognitive Behavioural Therapy (CBT) out...
Objectives: To determine the effectiveness and tolerability of acamprosate in comparison to placebo...
A population of 127 alcoholics of both sexes, hospitalized and weaned (DSM III diagnose: Alcohol Abu...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...